M&A Reporting, CTFN

Jonathan Spitzer

M&A Reporting

CTFN

Bringing the marketplace leading coverage of mergers, events, and major corporate actions, CTFN has a team of seasoned reporters from Los Angeles to London, publishing news that advances stories that matter to event-driven investors and deal professionals.

Event-Driven

<p>Pharma and biotech mergers look set to continue apace as players reposition within the industry, especially on the generics side.. Biosimilars are a likely area of new activity and market disruption as the fist such offerings gains approval and their market impact grows.</p>

Pharma and biotech mergers look set to continue apace as players reposition within the industry, especially on the generics side.. Biosimilars are a likely area of new activity and market disruption as the fist such offerings gains approval and their market impact grows.

Biosimilars Seen Fueling Next Wave of Pharma Deals

United States

Mylan NV is a global generic and specialty pharmaceuticals company. The Company operates an active pharmaceutical ingredient manufacturer and runs a specialty business focused on respiratory, allergy, and psychiatric therapies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mylan NV (MYL US)

Biosimilars Seen Fueling Next Wave of Pharma Deals

Pharma and biotech mergers look set to continue apace as players reposition within the industry, especially on the generics side.. Biosimilars are...

CTFN

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)